At the time of writing, Moderna Inc [MRNA] stock is trading at $116.07, down -0.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MRNA shares have gain 0.10% over the last week, with a monthly amount drifted -24.97%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on February 26, 2024, when HSBC Securities downgraded its rating to a Reduce and also boosted its price target to $86 from $75. Previously, Oppenheimer upgraded its rating to Outperform on January 02, 2024, and kept the price target unchanged to $142. On November 29, 2023, Canaccord Genuity initiated with a Hold rating and assigned a price target of $82 on the stock. HSBC Securities upgraded its rating to a Hold and decreased its price target to $69 on November 03, 2023. Deutsche Bank downgraded its rating to a Sell and reduced its price target to $60 on November 02, 2023. TD Cowen downgraded its rating to Market Perform for this stock on August 04, 2023, and downed its price target to $125. In a note dated August 03, 2023, Deutsche Bank downgraded an Hold rating on this stock but restated the target price of $125.
For the past year, the stock price of Moderna Inc fluctuated between $62.55 and $170.47. Currently, Wall Street analysts expect the stock to reach $170.56 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $116.07 at the most recent close of the market. An investor can expect a potential return of 46.95% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
According to Moderna Inc [NASDAQ:MRNA], the company’s sales were 5.14B for trailing twelve months, which represents an -91.07% plunge. Gross Profit Margin for this corporation currently stands at 0.22% with Operating Profit Margin at -1.0%, Pretax Profit Margin comes in at -0.93%, and Net Profit Margin reading is -1.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.42 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 114.70 points at the first support level, and at 113.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 118.14, and for the 2nd resistance point, it is at 120.21.
Ratios To Look Out For
It is important to note that Moderna Inc [NASDAQ:MRNA] has a current ratio of 4.03. As well, the Quick Ratio is 3.91, while the Cash Ratio is 0.87. Considering the valuation of this stock, the price to sales ratio is 8.65, the price to book ratio is 3.47.
Transactions by insiders
Recent insider trading involved Mock James M, Chief Financial Officer, that happened on Jul 08 ’24 when 689.0 shares were sold. Director, AFEYAN NOUBAR completed a deal on Jun 26 ’24 to sell 15000.0 shares. Meanwhile, Director AFEYAN NOUBAR sold 15000.0 shares on Jun 18 ’24.
